PITNEY BOWES INC /DE/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PITNEY BOWES INC /DE/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.89B | Feb 20, 2026 |
| FY2024 | Dec 31, 2024 | $516.12M | Feb 21, 2025 |
| FY2024 | Sep 30, 2024 | $499.46M | Feb 21, 2025 |
| FY2024 | Jun 30, 2024 | $489.75M | Feb 21, 2025 |
| FY2024 | Mar 31, 2024 | $521.27M | Feb 21, 2025 |
| FY2024 | Dec 31, 2023 | $526.42M | Feb 21, 2025 |
| FY2024 | Sep 30, 2023 | $503.03M | Feb 21, 2025 |
| FY2024 | Jun 30, 2023 | $500.83M | Feb 21, 2025 |
| FY2024 | Mar 31, 2023 | $548.65M | Feb 21, 2025 |
| FY2024 | Dec 31, 2022 | $2.48B | Feb 21, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $2.63B | Feb 20, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2010 | Dec 31, 2010 | $730.42M | Feb 28, 2011 |
| FY2010 | Sep 30, 2010 | $679.41M | Feb 28, 2011 |
| FY2010 | Jun 30, 2010 | $645.31M | Feb 28, 2011 |
| FY2010 | Mar 31, 2010 | $691.79M | Feb 28, 2011 |
| FY2010 | Dec 31, 2009 | $755.19M | Feb 28, 2011 |
| FY2010 | Sep 30, 2009 | $688.37M | Feb 28, 2011 |
| FY2010 | Jun 30, 2009 | $685.60M | Feb 28, 2011 |
| FY2010 | Mar 31, 2009 | $701.99M | Feb 28, 2011 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $144.70M | Feb 20, 2026 |
| FY2024 | Dec 31, 2024 | ($37.37M) | Feb 21, 2025 |
| FY2024 | Sep 30, 2024 | ($138.47M) | Feb 21, 2025 |
| FY2024 | Jun 30, 2024 | ($24.87M) | Feb 21, 2025 |
| FY2024 | Mar 31, 2024 | ($2.89M) | Feb 21, 2025 |
| FY2024 | Dec 31, 2023 | ($223.84M) | Feb 21, 2025 |
| FY2024 | Sep 30, 2023 | ($12.52M) | Feb 21, 2025 |
| FY2024 | Jun 30, 2023 | ($141.54M) | Feb 21, 2025 |
| FY2024 | Mar 31, 2023 | ($7.74M) | Feb 21, 2025 |
| FY2024 | Dec 31, 2022 | $36.94M | Feb 21, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.28M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $31.96M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $29.49M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $35.46M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $46.78M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $38.38M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $51.26M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $58.52M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $60.86M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $107.38M | Feb 20, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $621.57M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $717.89M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $781.61M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $785.55M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $924.16M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $963.32M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $1.00B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $1.00B | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $1.03B | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $1.14B | Feb 20, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $383.26M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $229.17M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $80.09M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $175.04M | Feb 21, 2025 |
| FY2022 | Dec 31, 2021 | $301.52M | Feb 17, 2023 |
| FY2022 | Dec 31, 2020 | $301.97M | Feb 17, 2023 |
| FY2020 | Sep 30, 2020 | $191.17M | Feb 19, 2021 |
| FY2020 | Jun 30, 2020 | $86.42M | Feb 19, 2021 |
| FY2020 | Mar 31, 2020 | ($67.36M) | Feb 19, 2021 |
| FY2021 | Dec 31, 2019 | $267.88M | Feb 22, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $66.28M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $72.40M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $78.11M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $82.63M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $184.04M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $104.99M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $137.25M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $137.81M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $118.25M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $159.23M | Feb 20, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.17B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $3.40B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $4.27B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $4.74B | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $4.96B | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $5.22B | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $5.47B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $5.94B | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $6.63B | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $5.84B | Feb 20, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.97B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $3.98B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $4.64B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $4.68B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $4.85B | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $5.15B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $5.18B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $5.84B | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $6.50B | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $5.94B | Feb 22, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($802.36M) | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | ($578.43M) | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | ($368.58M) | Feb 20, 2026 |
| FY2025 | Dec 31, 2022 | $60.65M | Feb 20, 2026 |
| FY2024 | Dec 31, 2021 | $112.63M | Feb 21, 2025 |
| FY2023 | Dec 31, 2020 | $70.62M | Feb 20, 2024 |
| FY2022 | Dec 31, 2019 | $289.15M | Feb 17, 2023 |
| FY2021 | Dec 31, 2018 | $101.84M | Feb 22, 2022 |
| FY2020 | Dec 31, 2017 | $30.55M | Feb 19, 2021 |
| FY2019 | Dec 31, 2016 | ($103.66M) | Feb 20, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $746.69M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $721.00M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $734.41M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $851.34M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $1.14B | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $1.15B | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $1.32B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $1.33B | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $1.33B | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $1.40B | Feb 20, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.66B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $2.67B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $3.08B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $5.13B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $5.17B | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $5.21B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $5.44B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $5.28B | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $5.23B | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $5.11B | Feb 22, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $284.89M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $469.73M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $600.05M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $668.33M | Feb 21, 2025 |
| FY2022 | Dec 31, 2021 | $732.48M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $921.45M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $924.44M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $867.26M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $1.01B | Feb 20, 2019 |
| FY2018 | Dec 31, 2016 | $764.52M | Feb 20, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.99B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $1.92B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $2.15B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $2.21B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $2.32B | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $2.56B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $2.74B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $3.27B | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $3.83B | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $3.36B | Feb 22, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 20, 2026 |
| FY2024 | Dec 31, 2024 | 0 | Feb 21, 2025 |
| FY2024 | Sep 30, 2024 | 0 | Feb 21, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Feb 21, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Feb 21, 2025 |
| FY2024 | Dec 31, 2023 | (1) | Feb 21, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Feb 21, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Feb 21, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Feb 21, 2025 |
| FY2024 | Dec 31, 2022 | 0 | Feb 21, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 20, 2026 |
| FY2024 | Dec 31, 2024 | 0 | Feb 21, 2025 |
| FY2024 | Sep 30, 2024 | 0 | Feb 21, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Feb 21, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Feb 21, 2025 |
| FY2024 | Dec 31, 2023 | (1) | Feb 21, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Feb 21, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Feb 21, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Feb 21, 2025 |
| FY2024 | Dec 31, 2022 | 0 | Feb 21, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | 199.75M | Feb 23, 2012 |
| FY2010 | Dec 31, 2010 | 203.43M | Feb 28, 2011 |
| FY2010 | Dec 31, 2009 | 207.20M | Feb 28, 2011 |
| FY2010 | Dec 31, 2008 | 206.18M | Feb 28, 2011 |
| FY2010 | Dec 31, 2007 | 214.51M | Feb 28, 2011 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.06M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $35.96M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $35.22M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $34.72M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $34.80M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $34.29M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $35.36M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $140.50M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $139.49M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $140.61M | Feb 20, 2019 |